TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on TuHURA Biosciences (HURA – Research Report). The associated price target remains the same with $15.00.

Jason McCarthy has given his Buy rating due to a combination of factors that highlight TuHURA Biosciences’ promising position in the oncology sector. The company has recently secured significant funding through equity financing and warrant exercises, ensuring financial stability and the ability to advance its pipeline into 2026. Additionally, TuHURA is in the process of acquiring Kineta, Inc., which will bring an innovative anti-VISTA antibody into its portfolio, further strengthening its oncology pipeline.
TuHURA’s strategic advancements include progressing its lead asset, IFx-2.0, into a pivotal Phase 3 study for Merkel cell carcinoma, with the trial set to begin soon. The company is also preparing to initiate a Phase 2 study for acute myeloid leukemia, leveraging its unique delta receptor inhibitor. These developments, coupled with upcoming data updates and key events, position TuHURA to capture increased investor interest, making it an attractive Buy opportunity according to McCarthy.

HURA’s price has also changed dramatically for the past six months – from $6.060 to $2.890, which is a -52.31% drop .